Nisa Investment Advisors
SMMT icon

Nisa Investment Advisors’s Summit Therapeutics SMMT Stock Holding History

Nisa Investment Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.9K Sell
268
-8
-3% -$142 ﹤0.01% 2655
2026
Q1 		$5.23K Buy
276
+39
+16% +$631 ﹤0.01% 2445
2025
Q4 		$4.14K Sell
237
-64
-21% -$1.2K ﹤0.01% 2488
2025
Q3 		$6.22K Sell
301
-149
-33% -$3.61K ﹤0.01% 2397
2025
Q2 		$9.58K Sell
450
-1,257
-74% -$28.7K ﹤0.01% 2288
2025
Q1 		$32.9K Buy
1,707
+1,401
+458% +$28.1K ﹤0.01% 1718
2024
Q4 		$5.46K Buy
306
+28
+10% +$543 ﹤0.01% 2256
2024
Q3 		$6.09K Hold
278
– – ﹤0.01% 2187
2024
Q2 		$2.17K Buy
278
+188
+209% +$1.01K ﹤0.01% 2368
2024
Q1 		$373 Buy
+90
New +$358 ﹤0.01% 2551
2023
Q4 		– Sell
-90
Closed -$168 – 2738
2023
Q3 		$168 Sell
90
-4
-4% -$8 ﹤0.01% 2687
2023
Q2 		$236 Buy
+94
New +$172 ﹤0.01% 2690

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Nisa Investment Advisors's SMMT Position: Q2 2026 in Review

Nisa Investment Advisors reduced its Summit Therapeutics (SMMT) stake by 2.9% in Q2 2026, selling an estimated $142 and leaving 268 shares worth $3.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2655.

Nisa Investment Advisors first reported a position in SMMT in Q2 2023 and has held it in 12 quarters since. The position peaked at $32.9K in Q1 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Nisa Investment Advisors held 268 shares of Summit Therapeutics worth $3.9K as of Q2 2026.
  • Nisa Investment Advisors sold 8 Summit Therapeutics shares in Q2 2026, an estimated $142.
  • Summit Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2655 holding.
  • Nisa Investment Advisors first reported a position in Summit Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • Nisa Investment Advisors's Summit Therapeutics position peaked at $32.9K in Q1 2025.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.